AZD-2461 is a novel anticancer chemotherapeutic currently in clinical trials. This compound acts as a poly(ADP)-ribose polymerase-1 (PARP1) inhibitor, potentially beneficial in homologous recombination-deficient tumors such as BRCA1-associated cancers. Unlike most PARP inhibitors, AZD-2461 is not a substrate for P-glycoprotein and is thus unlikely to incur related resistance mechanisms.
| Cas No. | 1174043-16-3 |
|---|---|
| Purity | ≥98% |
| Formula | C22H22FN3O3 |
| Formula Wt. | 395.43 |
| IUPAC Name | 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one |
| Solubility | DMSO 79 mg/mL (199.78 mM) Ethanol 31 mg/mL (78.39 mM) Water Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Jaspers JE, Kersbergen A, Boon U, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013 Jan;3(1):68-81. PMID: 23103855.
